News

Adrenomed Supervisory Board appoints Jens Schneider-Mergener as CEO & Jens Zimmermann (CMO) joins the Executive Board

Details

Adrenomed announced today that its Supervisory Board has appointed two new members of the Executive Board. Dr. Jens Schneider-Mergener is CEO effective August 1, 2019 and Dr. Jens Zimmerman (CMO) joined the Executive Board effective July 1, 2019. Dr. Schneider-Mergener will succeed Dr. Gerald Möller, who is designated to join Adrenomed’s Supervisory Board. Dr. Schneider-Mergener brings more than 25 years of experience in the biotechnology industry, with a proven track record of successfully transforming a research-stage biotech business into a fully-integrated pharmaceutical company. 

Immatics and Celgene enter strategic collaboration to develop novel adoptive cell therapies

Details

Immatics and Celgene have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers. Immatics may develop T-Cell Receptor Engineered T-cell Therapy (TCR-T) programs against solid tumor targets discovered with Immatics’ XPRESIDENT® technology. Programs would utilize proprietary T-Cell Receptors (TCRs) identified by Immatics’ XCEPTOR® TCR discovery and engineering platform. If Immatics develops programs against the TCR-T targets, Immatics will be responsible for the development and validation of these programs through lead candidate stage, at which time Celgene may exercise opt-in rights and assume sole responsibility for further worldwide development, manufacturing and commercialization of the TCR-T-cell therapies. 

Themis announces exclusive license and research collaboration agreement with MSD to develop vaccine candidates

Details

Themis announced today a research collaboration and exclusive license agreement with MSD for the discovery and development of undisclosed vaccine candidates using Themis’ measles virus vector-based platform. Under the terms of the agreement, Themis will develop vaccine candidates against an undisclosed disease target. MSD will provide research funding and make an equity investment in Themis. In addition, Themis will be eligible to receive development and sales milestone payments up to the potential value of approx. USD 200 million as well as royalties on approved products from the collaboration. 

  1. Wellington Partners raises EUR 210 million life science fund
  2. Quanta raises $48 million in Series C funding round
  3. Immatics appoints Harpreet Singh as Chief Executive Officer
  4. Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication
© Wellington Partners, 2020.